These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 24259660

  • 1. Evaluation of dabigatran utilization and risk among hospitalized patients.
    Sidman E, Probst LA, Darko W, Miller CD.
    Ann Pharmacother; 2014 Mar; 48(3):349-53. PubMed ID: 24259660
    [Abstract] [Full Text] [Related]

  • 2. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L, Chen C, White J.
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
    Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, van Ryn J, Lehr T.
    Curr Med Res Opin; 2012 Feb; 28(2):195-201. PubMed ID: 22208675
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.
    Circulation; 2011 May 31; 123(21):2363-72. PubMed ID: 21576658
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep 31; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adherence to anticoagulant treatment with dabigatran in a real-world setting.
    Schulman S, Shortt B, Robinson M, Eikelboom JW.
    J Thromb Haemost; 2013 Jul 31; 11(7):1295-9. PubMed ID: 23855420
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.
    Ann Intern Med; 2011 Jan 04; 154(1):1-11. PubMed ID: 21041570
    [Abstract] [Full Text] [Related]

  • 17. [Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation].
    Silva Miguel L, Rocha E, Ferreira J.
    Rev Port Cardiol; 2013 Jan 04; 32(7-8):557-65. PubMed ID: 23890991
    [Abstract] [Full Text] [Related]

  • 18. Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.
    Carley B, Griesbach S, Larson T, Krueger K.
    Am J Cardiol; 2014 Feb 15; 113(4):650-4. PubMed ID: 24484861
    [Abstract] [Full Text] [Related]

  • 19. Drug-induced exanthem following dabigatran.
    Whitehead H, Boyd JM, Blais DM, Hummel J.
    Ann Pharmacother; 2011 Oct 15; 45(10):e53. PubMed ID: 21881034
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.